Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | CHKA | P35790 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3551226 | 0.82 | PRMT6 (0.45) | ACHESIGMAR1 | |
| SCHEMBL3551208 | 0.77 | SLC6A3 (0.43) | SLC6A4SIGMAR1 | |
| SCHEMBL3550203 | 0.76 | ALDH1A1 (0.41) | LSS | |
| SCHEMBL13344517 | 0.75 | MEN1 (0.40) | ACHEKMT2A | |
| SCHEMBL3550805 | 0.71 | CXCR4 (0.43) | KMT2ASIGMAR1 | |
| SCHEMBL3548022 | 0.71 | ALDH1A1 (0.44) | CYP1A2KMT2ADPP4SIGMAR1 | |
| SCHEMBL5146706 | 0.71 | CXCR4 (0.43) | KMT2ASIGMAR1 | |
| SCHEMBL8625212 | 0.69 | CYP1A2 (0.52) | ACHEHRH3CYP1A2CYP2A6KMT2A | |
| SCHEMBL6186952 | 0.68 | HRH3 (0.69) | ACHEHRH3KMT2ASLC6A4PKM | |
| SCHEMBL13323425 | 0.68 | SLC6A4 (0.52) | ACHECHKASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714021-B2 | Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO., INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080287523-A1 | Pyrrolidin-3-Yl Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LLC | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287523-A1 | Pyrrolidin-3-Yl Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | BACE1, BACE2, APP | ACHE 42/4885HRH3 3091/4885CHKA 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.